Hemostatic Gels Market

Hemostatic Gels Market Outlook (2022 to 2032)

The global hemostatic gels market was valued at USD 957.1 Million in 2021, and is expected to expand at a CAGR of 6.8% to reach USD 1.9 Billion by 2032. According to a recent study by Future Market Insights, porcine-based hemostatic gels are leading the market with a market share of about 45% in 2021 among the material types.

Data Points	Market Insights
Hemostatic Gels Market Base Year Value (2021)	USD 957.1 Million
Estimated Market Size (2022)	USD 1.0 Billion
Projected Market Valuation (2032)	USD 1.9 Billion
Value-based CAGR (2022 to 2032)	6.8%
Market Share of Top 5 Countries	45.9%

Hemostatic gel is used as an assistant or alternative to hemostat devices to manage bleeding or wound closure. Blood loss is one of the main causes of death in physical trauma. It is important to manage blood loss and achieve quicker clotting than the natural clotting process which is occurred in the body.

To achieve blood clotting more quickly, physicians occasionally use hemostatic agents such as a hemostatic gel. These gels may promote clotting and thereby stop or control bleeding.

2017 to 2021 Hemostatic Gels Market Historic Outlook Vs 2022 to 2032 Forecast

The market value for hemostatic gels was approximately 21.8% of the overall USD 4.3 Billion of the global hemostats market in 2021. Sales of hemostatic gels increased at a CAGR of 5.4% between 2017 to 2021, owing to the growing volume of surgical procedures.

Growing interest in developing new hemostatic agents is due to unmet needs in modifying uncontrolled hemorrhages in emergency care, surgical procedures, and frontline situations. Even though a wide range of hemostats are available, the development of ideal hemostatic agents such as hemostatic gel formulations that offer including the ability to successfully and instantly manage blood loss, excellent mechanical properties, biocompatibility, antibacterial effect, strong tissue adhesion properties, and biodegradability, under wet and active conditions, remains a challenge.

Benefiting from biocompatibility, high porosity, injectability, and ease of handling, polymeric hydrogels with outstanding hemostatic properties have been receiving consideration over the last decade. Furthermore, the development of novel technologies to cater to the demand for high-quality gel-forming hemostatic agents will drive the overall hemostatic gels market.

The market is projected to witness lucrative growth during forecast period owing to increasing volumes of surgical procedures. According to WHO, annually, a surprising 310 million major surgeries are performed globally; and in USA and Europe, approximately 45 and 20 million surgeries are carried out respectively every year. This is attributed to the growing prevalence of obesity and other lifestyle diseases, rising prevalence of orthopaedic disease, and the growing occurrence of spinal and sports-related injuries.

Moreover, in both developed and emerging countries the number of hospitals and surgical centers is growing. The demand for hemostats such as hemostatic gels is high in these newly established hospitals and surgical centers due to the growing patient population base.

For instance, in the last quarter of 2020, UK Prime Minister Boris Johnson declared an investment of US4 4.3 Billion for 40 hospitals and certain schemes for upcoming funding for 48 hospitals by 2030.

Also, Steward Health Care in March 2021 announced plans to construct a new hospital in Washington. Thus, owing to the above-mentioned factors, the global hemostatic gels market is expected to grow at a CAGR of 6.8% during the forecast period.

Download Report Brochure

What are the Key Opportunities for Hemostatic Gels Manufacturers?

Hemostasis has high clinical importance in preventive, surgical, and emergency circumstances as blood loss may cause substantial diseases and deaths in civil and military individuals owing to bleeding problems rising from surgery, trauma injuries, and as hereditary, disease-related, or drug-induced blood syndromes.

For externally accessible injuries, a range of natural and synthetic biomaterials have to go through strong research, leading to hemostatic technologies including bandages, dressings, fibrin glues, tourniquets, tamponades, and hemostatic powders.

In contrast, treatment of internal non-compressible hemorrhage still severely relies on transfusion of pure blood or blood hemostatic components such as platelets, coagulation factors, and fibrinogens. Transfusion of platelets may experience significant challenges of high cost, limited availability, contamination risks, short shelf-life, performance variability, low portability, and immunological adverse reactions.

The usage of these blood hemostatic components provides only partial mechanisms for hemostasis. Through such concerns, interdisciplinary research is being conducted for the development of hemostatic gels that can be manufactured conveniently, and administered intravenously to mimic, leverage, and amplify physiological hemostatic mechanisms. This is expected to create opportunities for growth in the market for the development of effective and efficient hemostats.

Country-wise Insights

What is Driving the USA Hemostatic Gels Market?

Increasing Incidence of Lifestyle Related Disorders is Driving Demand for Hemostatic Gels

The USA dominated the North America hemostatic gels market, accounting for 82% of the total markets share in 2021. Rising prevalence of cardiovascular disorders, diabetes, and cancer in the USA. is propelling the volume of surgical procedures, thereby necessitating hemostatic gels.

With the global rise in the incidence of chronic diseases, the volume of surgical procedures is expected to increase in the forthcoming years, which is expected to drive demand hemostatic gels for blood loss management.

According to the CDC, around 150 million Americans are suffering from at least one chronic condition, which leads to the need for surgery. With the growing incidence of chronic diseases, the number of injuries and surgeries is expected to increase, thereby increasing the usage of hemostatic gels in the USA

What is the India Hemostatic Gels Market Outlook?

Rising Expenditure on Healthcare Infrastructure Will Augment Sales of Hemostatic Gels

Demand for hemostatic gels in India is set to increase at a 7.4% CAGR over the assessment period. The market in India is driven by increasing demand for hemostatic gels due to growing government initiatives to create awareness about the product.

For instance, in November 2020, the transport department of the Rajasthan government mandated the addition of feracrylum, a hemostatic gel, in the first aid of all vehicles that are being registered from November 2020 following a direction of the high court. Feracrylum has been recognized to be a hemostatic agent by several clinical studies.

Why the UK Hemostatic Gels Market Considered Lucrative?

Growing Trend of Medical Tourism in the UK Will Fuel the Adoption of Hemostatic Gels

Sales in the UK market are projected to increase at a 7.1% CAGR over the forecast period. As per the British heart foundation (UK) and its heart and circulatory disease statistics, in 2019, there has been a substantial surge in the number of cardiac surgeries such as aortic valve replacement and angioplasty in the UK

Hemostatic gels have higher application in cardiovascular surgeries due to better clinical outcomes compared to other wound closure techniques. Thus, a growing number of cardiac surgeries is expected to spur demand for effective hemostatic gels in the UK

What Makes the China Hemostatic Gels Market Attractive?

Increaisng Establishment of Hospitals and Ambulatory Centers in China Will Propel Demand for Hemostatic Gels

China held approximately 38.0% of the East Asia hemostatic gels market in 2021. As per the report, sales are forecast to grow at a 8.0% CAGR through 2032.

The government in China is investing heavily in the construction of healthcare infrastructure such as hospitals and clinics. As per an article published in 2020, China announced an investment of USD 4.6 Billion for the construction of hospitals in Wuhan.

There are now about 26,000 hospitals in China, more than in any other country; among them 60% are public and 40% are in the private sector. The significant growth in the number of hospitals and surgical centers is expected to boost sales of hemostatic gels.

Category-wise Insights

Which Hemostatic Gel Product Is Driving the Market?

Sales of Porcine-based Hemostatic Gels to Gain Traction

Based on product type, the porcine-based hemostatic gels segment held the highest market share of about 45% in 2021. As per the report, demand in the segment is expected to increase at a CAGR of 5.7% by the end of the forecast period. Ease of application, efficacy, biocompatibility, and cost-effectiveness are some of the key benefits offered by porcine-based hemostatic gels.

Which Indication Will Hold a Dominant Share in the Global Hemostatic Gels Market?

Adoption of Hemostatic Gels for Cardiovascular Surgeries Will Increase

In terms of indication, demand for hemostatic gels for cardiovascular surgeries will account for 33.1% of the total market share by 2032.Blood loss is one of the most common obstacle in cardiac surgeries, particularly following aortic involvements which leads to extended operating times, increased bleeding, and a higher risk of postoperative morbidity and mortality.

The use of hemostatic gels, especially in patients undergoing cardiac surgical procedures, is safe and effective in reducing time to hemostasis, reducing transfusion of blood products, and improving patient outcomes.

Competitive Landscape

Leading players operating in the global hemostatic gels market are launching innovative products to meet the demand for a hemostatic gel that can be easily and specifically applied, particularly for irregular fractures where bandages can be difficult, and powders are messy and can cause uneasiness. For instance:

• In July 2021, Medcura, Inc., and ASO, LLC collaboratively launched Rapid-Seal, a high-performance, antibacterial hemostatic gel which is available on several e-commerce sites and the shelves at a leading USA drugstore chain.
• In December 2021, Cresilon, Inc. submitted a 510(k) premarket notification to the USA FDA for its registered hemostatic gel which is followed by the successful launch of Cresilon's VETIGEL, an innovative hemostatic gel for the veterinary use.

With several competitors in hemostatic gels manufacturing, the overall market is highly fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships, and collaborations. For instance:

• In July 2021, Baxter International Inc. completed the acquisition of CryoLife, Inc. for certain assets related to PerClot, a polysaccharide hemostatic system for USD 60.8 Million.

Report Scope

Attributes	Details
Estimated Market Size (2022)	USD 1 Billion
Projected Market Valuation (2032)	USD 1.9 Billion
Value-based CAGR (2022-2032)	6.8%
Forecast Period	2017 to 2021
Historical Data Available for	2022 to 2032
Market Analysis	USD Billion for Value
Key Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa
Key Countries Covered	The USA, Canada, Brazil, Mexico, Argentina, the UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, and South Africa
Key Market Segments Covered	Material, Indication, End User, and Region
Key Companies Profiled	Baxter; Bio-Chem LLC; Clinician's Choice Dental Products Inc.;  Cresilon, Inc.; DSI Ltd.;  ENDOVISION CO., LTD; Ethicon US, LLC; F&A Medical; PrevestDenPro; Septodont; Teleflex Incorporated; Ultradent Products Inc. All; VladMiVa; Medcura, Inc.,

Key Market Segments Covered In Hemostatic Gels Industry Research

By Material:

• Bovine-Based
• Porcine-Based
• Polymer-Based

By Indication:

• General Surgery
• Dental Surgery
• Veterinary Surgery
• Cardiovascular Surgery
• Orthopaedic Surgery
• Others

By End-User:

• Hospitals
• Speciality Clinics
• Veterinary Settings
• Ambulatory Surgical Centers
• Online Sales

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• The Middle East and Africa (MEA)

Frequently Asked Questions

How much is the hemostatic gels market worth in 2021?

The global hemostatic gels market is worth USD 957.1 Million in 2021 and is set to expand 2.1X over the next ten years.

What is the sales forecast for the hemostatic gels market through 2032?

The hemostatic gels market is expected to reach USD 1.9 Billion by the end of 2032, with sales revenue expected to register at 6.8% CAGR.

What are the key trends shaping the hemostatic gels industry?

The growing volume of surgical procedures and the increasing need for hemostatic gels in blood loss management are some of the key trends in this market.

Which are the top 5 countries driving demand for hemostatic gels?

The USA the UK, India, China, and Brazil are expected to drive demand for the hemostatic gels industry.

What is the North American market outlook for hemostatic gels?

North America is one of the key markets for hemostatic gels, with the USA accounting for about 82% of the North American hemostatic gels market in the year 2021.

At what percentage is the demand for hemostatic gels expected to register growth in Europe?

Demand for hemostatic gels in Europe is expected to register a growth of 7.1% over the next ten years.

Which countries are the key producers of hemostatic gels?

The USA, the UK, India, and China are the key producers of hemostatic gels.

Who are the key players in the hemostatic gels market sphere?

Baxter, Bio-Chem LLC, Clinician's Choice Dental Products Inc., Cresilon, Inc., Dsi Ltd., Endovision Co., Ltd, Ethicon US, LLC, F&A Medical, Prevestdenpro, Septodont, Teleflex Incorporated, Ultradent Products Inc. All, Vladmiva And Medcura, Inc., Are Some Of The Key Players In The Hemostatic Gels Industry.